title: Nivolumab therapy before vemurafenib administration induces a severe skin rash.
authors.affiliation: Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital, Tokyo, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Imafuku
authors.affiliation: Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital, Tokyo, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Yoshino
authors.affiliation: Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital, Tokyo, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Ymaguchi
authors.affiliation: Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital, Tokyo, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Tsuboi
authors.affiliation: Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital, Tokyo, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Ohara
authors.affiliation: Department of Dermatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Hata
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000074322:Antineoplastic Agents, Immunological / Q000009:adverse effects; D005076:Exanthema / Q000139:chemically induced* / Q000175:diagnosis; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy; D008875:Middle Aged; D000077594:Nivolumab / Q000009:adverse effects* / Q000627:therapeutic use; D012720:Severity of Illness Index; D012878:Skin Neoplasms / Q000188:drug therapy; D000077484:Vemurafenib / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D000074322:Antineoplastic Agents, Immunological; D000077484:Vemurafenib; D000077594:Nivolumab